Core Viewpoint - OMass Therapeutics has entered into an exclusive collaboration and licensing agreement with Genentech, a member of Roche Group, to develop and commercialize OMass's oral small molecule project targeting inflammatory bowel disease (IBD) [1][3] Group 1: Financial Terms - OMass will receive an upfront payment of $20 million, with potential milestone payments exceeding $400 million related to preclinical, development, commercial, and net sales achievements [3] - OMass is also eligible for tiered royalties based on net sales [3] Group 2: Project Development Responsibilities - OMass will lead the initial preclinical development of the project until a candidate compound is selected [3] - Genentech will be responsible for clinical development, regulatory submissions, manufacturing, and commercialization activities [3]